Clinical Trials Logo

Clinical Trial Details — Status: Completed

Administrative data

NCT number NCT04008966
Other study ID # 58
Secondary ID
Status Completed
Phase Phase 4
First received
Last updated
Start date July 20, 2016
Est. completion date July 1, 2019

Study information

Verified date July 2019
Source Cairo University
Contact n/a
Is FDA regulated No
Health authority
Study type Interventional

Clinical Trial Summary

All participants started with a combination of recombinant FSH 300 U and urinary Gn 150 U from the 2nd day of the cycle then the dose was adjusted according to the ovarian response

From day 6 of the cycle, follow up using transvaginal ultrasound was done either daily or on alternate days according to the ovarian response. When the leading follicle reached 12 mm, GnRH antagonist was started using Cetrotide 0.25 subcutaneously daily till the day of triggering. Triggering was done when at least 3 follicles larger than 14 mm and at least one of them reached a mean diameter of 17 mm or more.

At the day of triggering, women were randomized into 2 groups. Group I (single trigger group) that included 80 women who received triggering in the form of 10,000 IU of HCG intramuscular injection. Group II (Dual trigger group) that included 80 women who received triggering in the form of 10,000 IU of HCG intramuscular injection in addition to GnRH agonist triptorelin 0.2 mg subcutaneously.

Ovum pickup was done 34 hours after triggering under the guidance of transvaginal ultrasound.

ISM1 culture medium was used for oocyte collection and embryo culture. Transabdominal ultrasound guided embryo transfer was done 3 days after oocyte retrieval using Labotect semirigid catheter by the same expert operator

Cycle cancellation was done if day 9 folliculometry revealed less than 2 mature follicles, no oocytes were retrieved or if fertilization failed

Luteal phase support was started in all women on the day of oocyte retrieval and continued till the day of serum β-hCG assessment (done 14 days after ET) through administration of 400 mg of natural Progesterone twice daily per vagina . In women with +ve serum β-hCG (> 5 mIU/ml), transvaginal ultrasound evaluation was done 4 weeks after ET to confirm the presence and number of intrauterine gestational sacs.


Description:

All participants started with a combination of recombinant FSH 300 U and urinary Gn 150 U from the 2nd day of the cycle then the dose was adjusted according to the ovarian response evaluated by transvaginal ultrasound and serum E2. Delayed start

From day 6 of the cycle, follow up using transvaginal ultrasound was done either daily or on alternate days according to the ovarian response. Ultrasound follow up reported number and size of follicles in each ovary and the endometrial thickness and pattern. When the leading follicle reached 12 mm, GnRH antagonist was started using Cetrotide 0.25 subcutaneously daily till the day of triggering. Triggering was done when at least 3 follicles larger than 14 mm and at least one of them reached a mean diameter of 17 mm or more.

At the day of triggering, women were randomized into 2 groups. Group I (single trigger group) that included 80 women who received triggering in the form of 10,000 IU of HCG intramuscular injection. Group II (Dual trigger group) that included 80 women who received triggering in the form of 10,000 IU of HCG intramuscular injection in addition to GnRH agonist triptorelin 0.2 mg subcutaneously.

Ovum pickup was done 34 hours after triggering under the guidance of transvaginal ultrasound.

ISM1 culture medium was used for oocyte collection and embryo culture. Transabdominal ultrasound guided embryo transfer was done 3 days after oocyte retrieval using Labotect semirigid catheter by the same expert operator

Cycle cancellation was done if day 9 folliculometry revealed less than 2 mature follicles, no oocytes were retrieved or if fertilization failed

Luteal phase support was started in all women on the day of oocyte retrieval and continued till the day of serum β-hCG assessment (done 14 days after ET) through administration of 400 mg of natural Progesterone twice daily per vagina . In women with +ve serum β-hCG (> 5 mIU/ml), transvaginal ultrasound evaluation was done 4 weeks after ET to confirm the presence and number of intrauterine gestational sacs.


Recruitment information / eligibility

Status Completed
Enrollment 160
Est. completion date July 1, 2019
Est. primary completion date June 2, 2019
Accepts healthy volunteers No
Gender Female
Age group 25 Years to 42 Years
Eligibility Inclusion Criteria:

- women with poor ovarian response candidate for ICSI

- women with spontaneous normal menstrual cycle

- normal uterine cavity

Exclusion Criteria:

- women with ovarian cysts

- endometriosis

- hydrosalpinx

- endocrinological disorders as hyperprolactinemia, thyroid or adrenal disorders.

- Couples with azospermic male partner

- those with severe uncontrolled medical or metabolic disorders

Study Design


Related Conditions & MeSH terms


Intervention

Drug:
combined oral contaraceptive pills
1 tablet daily between days 5 and 25 of the cycle before stimulation
recombinant FSH
300 U from the 2nd day of the cycle then the dose was adjusted according to the ovarian response evaluated by transvaginal ultrasound and serum E2
Urinaru gonadotropin
150 U from the 2nd day of the cycle then the dose was adjusted according to the ovarian response evaluated by transvaginal ultrasound and serum E2
GnRH antagonist
0.25 subcutaneously daily from the day in which the leading follicles reached 12 mm till the day of triggering
Human chorionic gonadotropin
10,000 IU intramuscular when at least 3 follicles larger than 14 mm and at least one of them reached a mean diameter of 17 mm or more
GnRH agonist
0.2 mg subcutaneously when at least 3 follicles larger than 14 mm and at least one of them reached a mean diameter of 17 mm or more
Procedure:
Ovum pick up
34 hours after triggering under the guidance of transvaginal ultrasound
Embryo transfer
Transabdominal ultrasound guided embryo transfer was done 3 days after oocyte retrieval using Labotect semirigid catheter
Drug:
natural Progesterone
400 mg twice daily per vagina

Locations

Country Name City State
Egypt Kasr Alainy medical school Cairo

Sponsors (1)

Lead Sponsor Collaborator
Cairo University

Country where clinical trial is conducted

Egypt, 

Outcome

Type Measure Description Time frame Safety issue
Primary number of mature follicular count number of follicles larger than 14 mm 10 - 14 days of the cycle
See also
  Status Clinical Trial Phase
Recruiting NCT05783349 - Predictive Value of Th1, Th2 and Th17 Cytokines on the Success of Embryo Implantation (ImmuNoFertilité) N/A
Completed NCT02154958 - Role of Follicular Output Rate in the Prediction of in Vitro Fertilization and Intracytoplasmic Sperm Injection in Women With Unexplained Infertility N/A
Not yet recruiting NCT05356429 - Small Molecule LCDM and GV Oocyte
Recruiting NCT03904355 - Effects of Intramural Fibroids on IVF Outcome N/A
Recruiting NCT06408948 - A Study to Evaluate the Mass Balance of [14C]SHR7280 in Healthy Adult Volunteers Phase 1
Completed NCT03948022 - Luteal Support in Frozen-Thawed Embryo Transfer Cycles Phase 4
Recruiting NCT02158026 - Evaluation of the Role of Follicular Sensitivity Index in the Prediction of Pregnancy in Women Undergoing ICSI/IVF Without Polycystic Ovarian Syndrome N/A
Completed NCT02784457 - Gonadotropin Releasing Hormone Antagonist in Treatment of Early-onset Severe Ovarian Hyperstimulation Syndrome Phase 2
Recruiting NCT04426942 - Sexuality in Medically Assisted Procreation Pregnancies
Completed NCT03820167 - Mitochondrial DNA in Fresh Versus Frozen Embryo Culture Media of PCOS Women Undergoing In Vitro Fertilization
Completed NCT04556630 - Experience of Lock Down Related to the Covid-19 Epidemic and Its Impact on the Project of Parenthood
Recruiting NCT02412605 - Effect of Trophectoderm Biopsy for Sex Selection on the Pregnancy and Miscarriage Rates of Women Undergoing IVF/ICSI N/A